Twenty-Two Years Without a New Antibiotic. The Chemistry Was Always There.

The Antimicrobial Pipeline Is Empty. The Chemistry Isn’t.

The last clinically meaningful new class of antibiotic, the lipopeptides (daptomycin), was introduced in 2003 (Steenbergen et al., 2005). The last new class of antifungal, the echinocandins (caspofungin), was introduced in 2001 (Letscher-Bru & Herbrecht, 2003).

Twenty-two and twenty-four years, respectively, of no genuinely new structural families entering medicine. Iterations on existing scaffolds, yes. Combination therapies, yes. New formulations, yes. But not new chemistry classes.

This is not because there is nothing left to find.

The field has been chemistry-starved because the way it has been looking for chemistry stopped working.

For decades, antimicrobial discovery followed a single-molecule logic. Screen a library. Identify a hit. Optimize the lead. Patent the structure. File the IND. The architecture of the pipeline assumed that one compound, refined for one target, would become one drug.

That logic produced beta-lactams, aminoglycosides, macrolides, fluoroquinolones, and most of the antimicrobial chemistry currently in clinical use. It worked, for a while.

It stopped working because biology stopped cooperating.

Pathogens are not stable targets. They adapt around single-compound pressure through a range of resistance mechanisms (Blair et al., 2015). The single-molecule approach generates resistance as a near-deterministic consequence of its own architecture. Each new lead lasts a shorter clinical lifespan than the last. Each new class fails to arrive at all (Theuretzbacher et al., 2020).

Meanwhile, the natural-product reservoir that produced approximately half of all approved drugs (Newman & Cragg, 2020) was progressively deprioritized. Plant secondary metabolomes, microbial natural products, fungal-derived chemistry. All of it was considered too complex, too unpredictable, too difficult to fit into the screening logic that defined the era (Atanasov et al., 2021).

But complex multi-compound systems are exactly what biology produces.

And exactly what biology resists most slowly.

A plant defending itself against a pathogen does not deploy one molecule. It deploys a coordinated chemical complement, often dozens of compounds acting in concert (Bednarek & Osbourn, 2009; VanEtten et al., 1994). The pathogen cannot evolve resistance to all of them simultaneously. The defense holds.

When that complement is studied in its natural configuration, rather than fractionated into single molecules and discarded for being too complex, different things become possible. This is the foundational premise of network pharmacology, an emerging paradigm that treats biological systems as networks of interacting components rather than as collections of isolated targets (Hopkins, 2008).

We have observed inhibition of pathogens spanning bacterial, fungal, and oomycete kingdoms from a single biological source. Not closely related organisms. Not similar infection strategies. Activity demonstrated across dozens of pathogen species, sustained at commercially viable concentrations.

That pattern does not emerge from single-molecule libraries. It emerges from intact multi-compound systems that align with how biology actually defends itself.

The implication is structural.

The antimicrobial pipeline has not failed because the chemistry ran out. It failed because the methodology ran out. And a methodology mismatched with biology cannot find what biology already contains.

The chemistry has been there the entire time.

It has been sitting in plant defense systems, microbial fermentations, fungal secondary metabolomes, and tree bark.

The question was never whether the molecules existed.

The question was whether anyone would look at them the way biology built them.

There is a second question, equally structural, that determines what happens after the chemistry is found.

What is it for?

Pharmaceutical chemistry is a tool. Tools are shaped by the hands that build them and the structures that fund them. A drug developed for the maximum return on investment will be priced for the populations who can pay. A drug developed for the populations who need it most will look different.

The platform we have been building exists because the people who most need broad-spectrum antimicrobial chemistry are also the people who can least afford the way modern pharmacology delivers it. Invasive fungal infection is most lethal in immunocompromised patients in low-resource healthcare systems. Antimicrobial-resistant bacterial infection kills disproportionately in the parts of the world with the least access to second-line therapies (Murray et al., 2022). Crop pathogens cause 17 to 30 percent of global losses on major food crops (Savary et al., 2019), and those losses fall hardest on the food systems with the thinnest margins.

The same chemistry that addresses these problems can be deployed two ways. It can be optimized for the highest-paying markets and developed at the slowest pace consistent with maximum exclusivity. That is the standard path. Or it can be developed under a structure where the economic outcome is decoupled from a quick exit, where mission alignment is operationally locked in, and where the proceeds of the work are committed, in advance, to the populations who need it most.

The mission this platform has been built to serve:

We would rather feed the hungry than watch our bank accounts grow. Not everyone is afforded the same chances in life, nor the same physical ability. This technology is for those people.

The pledge that operationalizes the mission:

As the founder of KR-Biosystems, I have personally pledged 99% of my share proceeds to The Peace Harvest, a charitable initiative addressing world hunger and environmental health. The pledge applies to my founder shares only and does not affect investor equity, returns, or exit economics. I will implement the legal vehicle at the first material liquidity event. The intent is durable. The commitment is public.

The pledge is not adjacent to the science. It is part of how the science works.

A founder whose economic motivation is locked to the long-term mission is structurally less likely to take a quick exit. A platform built under credible mission lock recruits scientists, engineers, and operators willing to work on something they believe in. A company committed in advance to the populations who need it most behaves differently in regulatory, partnership, and pricing conversations than a company that has not made that commitment.

These are not soft signals. They affect how fast the work moves, how durably the science holds, and how far it reaches.

We are not trying to escape biotech economics. We are trying to align biotech economics with biology’s actual purpose.

Biology adapts to feed itself, defend itself, and continue.

It is time pharmaceutical chemistry was developed to do the same.

References

Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews Drug Discovery, 20(3), 200–216. https://doi.org/10.1038/s41573-020-00114-z

Bednarek, P., & Osbourn, A. (2009). Plant–microbe interactions: Chemical diversity in plant defense. Science, 324(5928), 746–748. https://doi.org/10.1126/science.1171661

Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015). Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology, 13(1), 42–51. https://doi.org/10.1038/nrmicro3380

Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690. https://doi.org/10.1038/nchembio.118

Letscher-Bru, V., & Herbrecht, R. (2003). Caspofungin: The first representative of a new antifungal class. Journal of Antimicrobial Chemotherapy, 51(3), 513–521. https://doi.org/10.1093/jac/dkg117

Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., … Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0

Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770–803. https://doi.org/10.1021/acs.jnatprod.9b01285

Savary, S., Willocquet, L., Pethybridge, S. J., Esker, P., McRoberts, N., & Nelson, A. (2019). The global burden of pathogens and pests on major food crops. Nature Ecology & Evolution, 3(3), 430–439. https://doi.org/10.1038/s41559-018-0793-y

Steenbergen, J. N., Alder, J., Thorne, G. M., & Tally, F. P. (2005). Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections. Journal of Antimicrobial Chemotherapy, 55(3), 283–288. https://doi.org/10.1093/jac/dkh546

Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020). The global preclinical antibacterial pipeline. Nature Reviews Microbiology, 18(5), 275–285. https://doi.org/10.1038/s41579-019-0288-0

VanEtten, H. D., Mansfield, J. W., Bailey, J. A., & Farmer, E. E. (1994). Two classes of plant antibiotics: Phytoalexins versus “phytoanticipins.” The Plant Cell, 6(9), 1191–1192. https://doi.org/10.1105/tpc.6.9.1191

World Health Organization. (2022). WHO fungal priority pathogens list to guide research, development and public health action. World Health Organization. https://www.who.int/publications/i/item/9789240060241